Page last updated: 2024-11-04

vorinostat and Diabetes Mellitus, Type 2

vorinostat has been researched along with Diabetes Mellitus, Type 2 in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Grigolon, G1
Araldi, E1
Erni, R1
Wu, JY1
Thomas, C1
La Fortezza, M1
Laube, B1
Pöhlmann, D1
Stoffel, M1
Zarse, K1
Carreira, EM1
Ristow, M1
Fischer, F1

Other Studies

1 other study available for vorinostat and Diabetes Mellitus, Type 2

ArticleYear
Grainyhead 1 acts as a drug-inducible conserved transcriptional regulator linked to insulin signaling and lifespan.
    Nature communications, 2022, 01-10, Volume: 13, Issue:1

    Topics: Animals; Animals, Genetically Modified; Blood Glucose; Caenorhabditis elegans; Caenorhabditis elegan

2022